Atrium Therapeutics, Inc. (RNA)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Peers in Healthcare
Atrium Therapeutics, Inc. has no peer companies in this window.
Recent press releases
Atrium Therapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →Atrium Therapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Atrium Therapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Atrium Therapeutics, Inc. in this window.
People at Atrium Therapeutics, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Atrium Therapeutics, Inc..